Alnylam Pharmaceuticals (ALNY) news

Alnylam Pharmaceuticals, Inc.: RBC cuts target price to $345 from $350

Adarx Pharma said to guide IPO pricing to top of range or above

ADARx Pharmaceuticals is expected to price its upcoming Nasdaq IPO at or above the top of its $15–$17 per share range, according to recent market signals and investor sentiment. The company is offering 21.875 million shares in the offering, which could raise up to $350 million and value the firm at…

Alnylam shares down 4.9% premarket after rival trial data

Alnylam Pharmaceuticals (ALNY) shares fell 4.9% in premarket trading following the release of data from a rival trial, marking a reversal from recent gains driven by setbacks in competing therapies for ATTR cardiomyopathy. Despite the recent rally, Alnylam’s stock has declined 25.34% year to date,…

Alnylam Pharmaceuticals (ALNY) fell 5.39% in intraday trading after rising 6.12% on Wednesday, marking a reversal of the prior session's move

Alnylam Pharmaceuticals (ALNY) shares rose 6.24% in intraday trading after BMO Capital Markets initiated coverage with an Outperform rating and a $318 price target.

Alnylam Pharmaceuticals (NASDAQ:ALNY) shares rose 6.24% in intraday trading after BMO Capital Markets initiated coverage with an Outperform rating and a $318 price target . The stock has faced downward pressure in recent months, declining 42.5% year-to-date and trading at $228.61, or 54% below its…